PAHC Stock Overview
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States.
Phibro Animal Health Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$18.70|
|52 Week High||US$26.55|
|52 Week Low||US$17.28|
|1 Month Change||-4.93%|
|3 Month Change||-0.16%|
|1 Year Change||-22.02%|
|3 Year Change||-39.29%|
|5 Year Change||-52.84%|
|Change since IPO||10.00%|
Recent News & Updates
Phibro Animal Health (NASDAQ:PAHC) Has Affirmed Its Dividend Of $0.12
Phibro Animal Health Corporation's ( NASDAQ:PAHC ) investors are due to receive a payment of $0.12 per share on 28th of...
Phibro Animal declares $0.12 dividend
Phibro Animal (NASDAQ:PAHC) declares $0.12/share quarterly dividend, in line with previous. Forward yield 2.56% Payable Sept. 28; for shareholders of record Sept. 7; ex-div Sept. 6. See PAHC Dividend Scorecard, Yield Chart, & Dividend Growth.
Phibro Animal Health's (NASDAQ:PAHC) Dividend Will Be US$0.12
Phibro Animal Health Corporation's ( NASDAQ:PAHC ) investors are due to receive a payment of US$0.12 per share on 22nd...
|PAHC||US Pharmaceuticals||US Market|
Return vs Industry: PAHC underperformed the US Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: PAHC underperformed the US Market which returned -12.8% over the past year.
|PAHC Average Weekly Movement||5.4%|
|Pharmaceuticals Industry Average Movement||11.8%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: PAHC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PAHC's weekly volatility (5%) has been stable over the past year.
About the Company
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Phibro Animal Health Fundamentals Summary
|PAHC fundamental statistics|
Is PAHC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PAHC income statement (TTM)|
|Cost of Revenue||US$630.39m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 24, 2022
|Earnings per share (EPS)||1.45|
|Net Profit Margin||6.48%|
How did PAHC perform over the long term?See historical performance and comparison
2.6%Current Dividend Yield
Does PAHC pay a reliable dividends?See PAHC dividend history and benchmarks
|Phibro Animal Health dividend dates|
|Ex Dividend Date||Sep 06 2022|
|Dividend Pay Date||Sep 28 2022|
|Days until Ex dividend||29 days|
|Days until Dividend pay date||51 days|
Does PAHC pay a reliable dividends?See PAHC dividend history and benchmarks
Is PAHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PAHC?
Other financial metrics that can be useful for relative valuation.
|What is PAHC's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does PAHC's PE Ratio compare to its peers?
|PAHC PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
AVIR Atea Pharmaceuticals
AMYT Amryt Pharma
TARO Taro Pharmaceutical Industries
PAHC Phibro Animal Health
Price-To-Earnings vs Peers: PAHC is good value based on its Price-To-Earnings Ratio (12.9x) compared to the peer average (46.6x).
Price to Earnings Ratio vs Industry
How does PAHC's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Earnings vs Industry: PAHC is good value based on its Price-To-Earnings Ratio (12.9x) compared to the US Pharmaceuticals industry average (19.3x)
Price to Earnings Ratio vs Fair Ratio
What is PAHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||12.9x|
|Fair PE Ratio||13.9x|
Price-To-Earnings vs Fair Ratio: PAHC is good value based on its Price-To-Earnings Ratio (12.9x) compared to the estimated Fair Price-To-Earnings Ratio (13.9x).
Share Price vs Fair Value
What is the Fair Price of PAHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: PAHC ($18.7) is trading above our estimate of fair value ($14.15)
Significantly Below Fair Value: PAHC is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Phibro Animal Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PAHC's earnings are forecast to decline over the next 3 years (-11.3% per year).
Earnings vs Market: PAHC's earnings are forecast to decline over the next 3 years (-11.3% per year).
High Growth Earnings: PAHC's earnings are forecast to decline over the next 3 years.
Revenue vs Market: PAHC's revenue (4.1% per year) is forecast to grow slower than the US market (7.9% per year).
High Growth Revenue: PAHC's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PAHC's Return on Equity is forecast to be low in 3 years time (18.8%).
Discover growth companies
How has Phibro Animal Health performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PAHC has high quality earnings.
Growing Profit Margin: PAHC's current net profit margins (6.5%) are higher than last year (5.4%).
Past Earnings Growth Analysis
Earnings Trend: PAHC's earnings have declined by 8.1% per year over the past 5 years.
Accelerating Growth: PAHC's earnings growth over the past year (37.1%) exceeds its 5-year average (-8.1% per year).
Earnings vs Industry: PAHC earnings growth over the past year (37.1%) exceeded the Pharmaceuticals industry 15.5%.
Return on Equity
High ROE: Whilst PAHC's Return on Equity (22.03%) is high, this metric is skewed due to their high level of debt.
Discover strong past performing companies
How is Phibro Animal Health's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PAHC's short term assets ($546.5M) exceed its short term liabilities ($187.1M).
Long Term Liabilities: PAHC's short term assets ($546.5M) exceed its long term liabilities ($462.1M).
Debt to Equity History and Analysis
Debt Level: PAHC's net debt to equity ratio (119.8%) is considered high.
Reducing Debt: PAHC's debt to equity ratio has reduced from 221.8% to 155.8% over the past 5 years.
Debt Coverage: PAHC's debt is not well covered by operating cash flow (8%).
Interest Coverage: PAHC's interest payments on its debt are well covered by EBIT (6x coverage).
Discover healthy companies
What is Phibro Animal Health current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: PAHC's dividend (2.57%) is higher than the bottom 25% of dividend payers in the US market (1.52%).
High Dividend: PAHC's dividend (2.57%) is low compared to the top 25% of dividend payers in the US market (4.09%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, PAHC has been paying a dividend for less than 10 years.
Growing Dividend: PAHC's dividend payments have increased, but the company has only paid a dividend for 8 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (33.1%), PAHC's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (2167.4%), PAHC's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jack Bendheim (75 yo)
Mr. Jack Clifford Bendheim has been the President and Chief Executive Officer of Phibro Animal Health Corporation since 1988 and March 2014, respectively and serves as its Chairman. Mr. Bendheim served as...
CEO Compensation Analysis
Compensation vs Market: Jack's total compensation ($USD4.00M) is about average for companies of similar size in the US market ($USD3.94M).
Compensation vs Earnings: Jack's compensation has increased by more than 20% in the past year.
Experienced Management: PAHC's management team is seasoned and experienced (5.4 years average tenure).
Experienced Board: PAHC's board of directors are seasoned and experienced ( 14.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Phibro Animal Health Corporation's employee growth, exchange listings and data sources
- Name: Phibro Animal Health Corporation
- Ticker: PAHC
- Exchange: NasdaqGM
- Founded: 1946
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$757.417m
- Shares outstanding: 40.50m
- Website: https://www.pahc.com
Number of Employees
- Phibro Animal Health Corporation
- Glenpointe Centre East
- 3rd Floor
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/06 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.